PEL

Piramal Enterprises Share Price

₹1,090.85
-31.8 (-2.83%)
18 September, 2024 02:45 BSE: 500302 NSE: PEL ISIN: INE140A01024

Start SIP in Piramal Enterprises

Start SIP

Piramal Enterprises Performance

Day Range

  • Low 1,086
  • High 1,126
₹ 1,090

52 Week Range

  • Low 737
  • High 1,144
₹ 1,090
  • Open Price1,125
  • Previous Close1,123
  • Volume675191

Piramal Enterprises Chart

  • Over 1 Month + 15.15%
  • Over 3 Month + 23.61%
  • Over 6 Month + 33.15%
  • Over 1 Year + 1.87%

Piramal Enterprises Key Statistics

P/E Ratio -12.2
PEG Ratio 0.1
Market Cap Cr
Price to Book Ratio 0.9
EPS 35.4
Dividend 0.9
Relative Strength Index 58.33
Money Flow Index 53.25
MACD Signal 25.34
Average True Range 39.28

Piramal Enterprises Investment Rating

  • Master Rating:
  • Piramal Enterprises has an operating revenue of Rs. 9,265.10 Cr. on a trailing 12-month basis. An annual revenue growth of 12% is good, Pre-tax margin of -34% needs improvement, ROE of -6% is poor and needs improvement. The stock from a technical standpoint is comfortably placed above its key moving averages, around 12% and 22% from 50DMA and 200DMA. It has recently broken out of a base in its weekly chart and is trading around 5% from the pivot point (which is the ideal buying range for a stock). From an O'Neil Methodology perspective, the stock has an EPS Rank of 9 which is a POOR score indicating inconsistency in earnings, a RS Rating of 50 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 149 indicates it belongs to a poor industry group of Finance-Commercial Loans and a Master Score of C is fair but needs to improve. Institutional holding has declined in the last reported quarter is a negative sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

EPS Strength

Price Strength

Buyer Demand

Group Rank

Piramal Enterprises Financials
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 5015466164861,194181
Operating Expenses Qtr Cr 47121739661627031
Operating Profit Qtr Cr 474784367153925150
Depreciation Qtr Cr 46652322
Interest Qtr Cr 197205188151201167
Tax Qtr Cr 68285-378415246
Net Profit Qtr Cr 228954-1,0603577-57
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 3,8254,837
Operating Expenses Annual Cr 1,5061,704
Operating Profit Annual in Cr 2,2293,082
Depreciation Cr 67323
Interest Annual Cr 745712
Tax Annual Cr 63-22
Net Profit Annual Cr 47414,333
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 3,091917
Cash from Investing Activity Annual Cr 167-37
Cash from Financing Annual Activity Cr -3,735-604
Net Cash Flow Annual Cr -476276
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 21,59224,034
Fixed Assets Annual Cr 7461,368
Total Non Current Assets Annual Cr 1,7362,573
Total Current Assets Annual Cr 28,07030,531
Total Assets Annual Cr 29,80633,104
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 9611,007
ROE Annual % 260
ROCE Annual % 611
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 6265
IndicatorJun 2024Mar 2024Dec 2023Sep 2023Jun 2023Mar 2023
Oper Rev Qtr Cr 2,0691,5962,4522,0092,8042,132
Operating Expenses Qtr Cr 1,2502,3031,1231,3202,3593,820
Operating Profit Qtr Cr 1,361-3671,2051,1181,713813
Depreciation Qtr Cr 5171241383741
Interest Qtr Cr 1,1961,1671,1031,0391,035991
Tax Qtr Cr 66-821-958111732
Net Profit Qtr Cr 181137-2,37848509-196
IndicatorMar 2024Mar 2023
Total Revenue Annual Cr 10,1789,087
Operating Expenses Annual Cr 6,3517,434
Operating Profit Annual in Cr 3,6691,500
Depreciation Cr 829123
Interest Annual Cr 4,3443,994
Tax Annual Cr -1,595-3,978
Net Profit Annual Cr -1,6849,969
IndicatorMar 2024Mar 2023
Cash from Operating Activity Annual Cr 261,359
Cash from Investing Activity Annual Cr -1,872-351
Cash from Financing Annual Activity Cr 1,390-3,325
Net Cash Flow Annual Cr -455-2,316
IndicatorMar 2024Mar 2023
Total ShareHolders Funds Annual Cr 26,55731,059
Fixed Assets Annual Cr 3,4072,997
Total Non Current Assets Annual Cr 7,9095,571
Total Current Assets Annual Cr 74,69678,181
Total Assets Annual Cr 82,60583,752
IndicatorMar 2024Mar 2023
Book Value Per Share Annual Rs 1,1821,301
ROE Annual % -632
ROCE Annual % 52
Total Debt to Total Equity Annual --
EBDIT Annual Margin % 3819

Piramal Enterprises Technicals

EMA & SMA

Current Price
₹1,090.85
-31.8 (-2.83%)
pointer
  • Bullish Moving Average
  • ___
  • 15
  • Bearish Moving Average
  • ___
  • 1
  • 20 Day
  • ₹1,059.69
  • 50 Day
  • ₹1,011.40
  • 100 Day
  • ₹967.71
  • 200 Day
  • ₹945.67
  • 20 Day
  • ₹1,064.28
  • 50 Day
  • ₹1,005.50
  • 100 Day
  • ₹936.33
  • 200 Day
  • ₹915.51

Piramal Enterprises Resistance and Support

PIVOT
₹1,101.04
Resistance
First Resistance 1,115.87
Second Resistance 1,140.88
Third Resistance 1,155.72
RSI 58.33
MFI 53.25
MACD Single Line 25.34
MACD 27.18
Support
First Support 1,076.02
Second Support 1,061.18
Third Supoort 1,036.17

Piramal Enterprises Delivery and Volume

Period NSE + BSE Volume Avg NSE + BSE Delivery Volume Avg NSE + BSE Delivery Volume %
Day 708,465 23,159,721 32.69
Week 1,484,752 38,796,580 26.13
1 Month 1,556,210 59,089,275 37.97
6 Month 1,682,547 68,933,970 40.97

Piramal Enterprises Result Highlights

Piramal Enterprises Synopsis

NSE-Finance-Commercial Loans

Piramal Enterprises is involved in the business activities of Other financial service activities, except insurance and pension funding activities. Company’s Total Operating Revenue is Rs. 3734.30 Cr. and Equity Capital is Rs. 44.93 Cr. for the Year ended 31/03/2024. Piramal Enterprises Ltd. is a Public Limited Listed company incorporated on 26/04/1947 and has its registered office in the State of Maharashtra, India. Company’s Corporate Identification Number(CIN) is L24110MH1947PLC005719 and registration number is 005719.
Market Cap 25,313
Sales 3,129
Shares in Float 12.18
No of funds 258
Yield 0.89
Book Value 1.17
U/D Vol ratio 1.6
LTDebt / Equity 17
Alpha -0.16
Beta 1.61

Piramal Enterprises Shareholding Pattern

Owner NameJun-24Mar-24Dec-23Sep-23
Promoters 46.03%46.19%46.19%46.19%
Mutual Funds 6.26%6.68%6.55%5.83%
Insurance Companies 5.34%5.45%5.25%5.12%
Foreign Portfolio Investors 16.19%16.97%17.19%19.69%
Financial Institutions/ Banks
Individual Investors 17.23%16.48%16.51%15.13%
Others 8.95%8.23%8.31%8.04%

Piramal Enterprises Management

Name Designation
Mr. Ajay G Piramal Chairman
Dr.(Mrs.) Swati A Piramal Vice Chairperson
Mr. Kunal Bahl Independent Director
Ms. Anjali Bansal Independent Director
Mr. Puneet Dalmia Independent Director
Mr. Gautam Doshi Independent Director
Mr. Anita George Independent Director
Mr. Rajiv Mehrishi Independent Director
Mr. Asheet Mehta Independent Director
Mr. Suhail Nathani Independent Director
Mr. Anand Piramal Non Executive Director
Ms. Nandini Piramal Non Executive Director
Mr. Vijay Shah Non Executive Director
Mr. Shikha Sharma Independent Director

Piramal Enterprises Forecast

Price Estimates

2,000(9.8%)
1,758(-3.5%)
1,590(-12.7%)

Other Analyst Rating

Piramal Enterprises Corporate Action

Date Purpose Remarks
2024-08-13 Quarterly Results
2024-05-08 Audited Results & Final Dividend
2024-01-29 Quarterly Results
2023-11-09 Quarterly Results
2023-07-28 Quarterly Results & Buy Back
Date Purpose Remarks
2024-07-05 FINAL Rs.10.00 per share(500%)Final Dividend
2023-06-16 FINAL Rs.31.00 per share(1550%)Final Dividend
2022-07-15 FINAL Rs.33.00 per share(1650%)Final Dividend
2021-07-07 FINAL Rs.33.00 per share(1650%)Final Dividend

About Piramal Enterprises

Piramal Enterprises Limited is an Indian multinational pharmaceutical and financial services company based in Mumbai, Maharashtra. Founded by Ajay Piramal (who is also the Chairman), the company operates in the pharmaceuticals, financial services and real estate sector.

He founded the company in 1984 after he acquired a small-scale manufacturing unit from his father. Today, Piramal has more than 50 offices across 30 countries and employs over 10,000 people worldwide. With a presence in 100+ countries through its subsidiaries or associate companies. Piramal has been ranked among Forbes Asia’s 200 Best Under A Billion in 2019.

Business Verticals

PEL's Global Pharma division has a strong product portfolio of niche differentiated branded generics that are difficult to manufacture, sell, or distribute. Through its worldwide network of facilities, PEL's Contract Development and Manufacturing Organisation (CDMO) services segment provide end-to-end solutions across the drug life cycle. 

The Indian consumer products division of PEL serves India’s self-care market. PEL's OTC portfolio includes 21 major pharmaceutical and personal care brands in diverse product categories such as Vitamins & Nutrition, Dermatological & Antacids, Analgesics, and Baby Care. PEL's Healthcare Insights & Analytics division is the world's leading provider of healthcare analytics data, insight products and services to the world's leading pharma, biotech and medical technology companies, allowing them to make informed business decisions.

PEL's financial services include wholesale lending, housing finance, and alternative asset management. Piramal Capital & Housing Finance Ltd, PEL's wholly-owned subsidiary, is registered as a housing finance company with National Housing Bank (NHB) and is involved in a variety of financial services businesses. It offers wholesale and retail funding opportunities across industries.

Company History

Piramal Enterprises was founded as Indian Schering Limited on April 26, 1947, by British Schering Ltd. With effect from September 27, 1979, the company's name was changed from Indian Schering Ltd to Nicholas Laboratories India Ltd. Gujarat Glass Ltd (GGL) was acquired with the company on April 1, 1990. The new formulation plant in Pithampur, Madhya Pradesh, was inaugurated in 1991. After a year, in 1992, the company established a second formulation plant in Pithampur, Madhya Pradesh, with cutting-edge manufacturing facilities. The company's name changed from 'Nicholas Laboratories Ltd' to 'Nicholas Piramal India Ltd' on December 2, 1992.
 

Milestones

1988
Entered the pharmaceutical industry with the purchase of Nicholas Laboratories.
A series of mergers and acquisitions, joint ventures and alliances, and organic initiatives.

2010
Over two decades, they built a leading Indian pharmaceutical company.
The Domestic Formulations business was sold to Abbott in 2010 for USD 3.8 billion. Diagnostic Services were sold to Super Religare Laboratories.

From 2020 onwards
Multiple capital raise initiatives helped to strengthen the balance sheet.
Through the sale of DRG and the exit of Shriram Transport, the organization structure was simplified.
Subsidized the pharmaceutical businesses and raised new capital from Carlyle Transforming Financial Services with the DHFL acquisition to deliver long-term growth and profitability.
 

Piramal Enterprises FAQs

What is Share Price of Piramal Enterprises ?

Piramal Enterprises share price is ₹1,090 As on 18 September, 2024 | 02:31

What is the Market Cap of Piramal Enterprises ?

The Market Cap of Piramal Enterprises is ₹24596.2 Cr As on 18 September, 2024 | 02:31

What is the P/E ratio of Piramal Enterprises ?

The P/E ratio of Piramal Enterprises is -12.2 As on 18 September, 2024 | 02:31

What is the PB ratio of Piramal Enterprises ?

The PB ratio of Piramal Enterprises is 0.9 As on 18 September, 2024 | 02:31

What were the company's most recent reported sales and net income?

Piramal Enterprises Ltd recorded net sales of INR 13993 crores in the year ending March 2022. 

What is the future of the company's shares?

Piramal Enterprises Ltd stock may be a good buy according to market analysts considering meaningful inroads into Retail led by mortgages and small-term loans via digital alliance.

How to buy shares of Piramal Enterprises Ltd.?

The company's shares can be bought online or offline by opening a Demat account with 5Paisa and verifying the KYC documents.

Q2FY23
Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91
 
footer_form